New approaches to identifying rare disease patients
While we have seen exponential growth in the effort to develop drugs to treat rare diseases in the 30 years since the Orphan Drug Act was introduced, unique...
Strategy in rare disease requires specialist expertise and understanding. CRA understands the unique challenges that rare disease companies face, and we implement a distinctive approach to help drive their success.
We are rare disease specialists.
CRA’s experience stems from hundreds of rare disease engagements across many therapeutic areas.
- 50+Rare disease areas covered
- 300+Rare disease engagements since 2017
Our rare disease offerings span across the product lifecycle.
- Early developmentDiscover
- Early PMA assessment
- Pipeline opportunity assessment
- Diagnostics & screening
- Incentives review
- Licensing / commercially reasonable efforts disputes
- Late developmentDevelop
- Market access & evidence generation strateg
- Payer value proposition
- Patient finding
- Landscape assessment & policy shaping
- LaunchDeliver
- Launch pricing strategy
- Payer negotiation
- Launch excellence
- Stakeholder engagement
- Competitive simulations
- Regulatory and P&R policies
- Uptake and diffusion
- Life cycle & LOEDefend
- Indication & geographic expansion
- Competitor response strategies
- Price/access/uptake benchmarking and assessments
- LOE strategies